Key facts
- It has raised $1.1M; the latest was Grant ($3.0M) in Jun 2025.
- Notable investors include Creative Destruction Lab, Endless Frontier Labs, Pillar VC, 2048 Ventures, Mission BioCapital — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Cloverleaf Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Cloverleaf Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Cloverleaf Bio
Developer of a Ribonucleic Acid (RNA) therapeutics development platform designed to revolutionize cancer therapy and patient outcomes in oncology. The company's platform allows for direct inhibition of various enzymes necessary for cancer growth from a single therapeutic molecule, enabling engineered tRNA therapeutics clinics to improve patient outcomes in oncology.
- Sector
- Healthcare
- HQ
- New Haven, CT, United States
- Founded
- 2023
- Employees
- 4
- Website
- cloverleafbio.com/
- Ownership
- Privately Held (backing)
Cloverleaf Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Cloverleaf Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Cloverleaf Bio in its N-PORT filings yet. We sweep new filings monthly.